Medical device development is usually described as a regulatory process: classification, documentation, conformity assessment, approval. That's accurate, but incomplete. Regulatory compliance runs in parallel with a design and engineering workstream that determines whether the device can pass that process at all.
Treating these as separate tracks – design first and regulatory second – is where projects lose time and budget. A design finalised without classification and testing requirements in mind can fail validation and force a redesign late in development, when changes are at their most expensive.
This guide covers the UK regulatory pathway as it stands in 2026, the standards that shape device design, and the engineering work that runs alongside all of it.
A medical device, under UK law, is any instrument, apparatus, software, or other article intended to diagnose, prevent, monitor, or treat disease, or to investigate or modify the body's anatomy or physiological processes. This comes from the UK Medical Devices Regulations 2002 (UK MDR 2002).
Medical device development is the full process of taking a device from concept to market: design, engineering, prototyping, verification and validation testing, and regulatory approval.
The MHRA regulates the medical devices market in Great Britain. All devices must be registered before sale. The fee structure changed on 1 April 2026: the old one-off fee is now an annual charge of £300 per year for each GMDN category a manufacturer's devices fall under.
Devices fall into four risk-based classes under the UK MDR 2002:
|
Class |
Risk level | Conformity route |
|---|---|---|
| Class I | Lowest | Self-declaration in most cases |
| Class IIa | Low to medium | UK Approved Body assessment required (e.g. quality system audit, type examination, or product verification) |
| Class IIb | Medium to high | UK Approved Body assessment required, typically including type‑examination or full quality assurance system audit. |
| Class III | Highest | UK Approved Body assessment, including detailed design examination and clinical data review. |
Manufacturers of non-sterile, non-measuring Class I devices can self-declare. Everything else needs UK Approved Body conformity assessment before the UKCA mark can be affixed. MHRA's borderline products guidance covers unclear cases.
On the UKCA and the CE transition: CE‑marked devices can still be sold in Great Britain under transitional arrangements: until 30 June 2028 for devices certified under the older EU Medical Devices Directive (MDD/AIMDD), and 30 June 2030 for devices certified under the EU MDR/IVDR. The MHRA ran a targeted consultation between February and April 2026 on extending or removing these deadlines. As of July 2026, no outcome has been published, so design against the current dates.
Separately, new GB post‑market surveillance requirements took effect on 16 June 2025 and apply to all devices on the GB market, including CE‑marked ones. This includes a GB‑specific PMS system, vigilance reporting for serious incidents and field safety corrective actions, and documented complaint handling.
On quality management: most UK Approved Bodies expect alignment with ISO 13485. A design partner does not need its own certification, but its processes must work within a client’s existing ISO 13485 system.
Northern Ireland follows EU MDR/IVDR and requires a CE mark (not UKCA). Selling across the whole UK means planning for both routes.
Medical devices also sit inside environmental legislation, which affects sustainable product design decisions: ISO 1400 for environmental management systems, the EU Batteries Regulation (2023/1542) (superseding the old Batteries Directive), REACH for chemical substances, RoHS 2 for hazardous substances in electronics, and the WEEE Directive for end‑of‑life disposal. Reprocessors of single‑use devices are treated as manufacturers under EU MDR Article 17. Packaging rules are also transitioning: the EU Waste Packaging Directive is being replaced by the PPWR, applying from 12 August 2026. Most of these frameworks are EU‑derived; a GB‑only manufacturer’s obligations will depend on the applicable UK regimes (e.g. UK REACH, UK RoHS, UK packaging rules), which may differ in scope and timing.
Our guide to medical device regulations and our broader look at how sustainability is influencing product design cover this in more depth.
Classification and testing requirements have to shape design decisions from the start, not get checked against them afterwards. Four things happen in parallel, all part of a broader product design consultancy:
These workstreams need to run together continuously. A device designed in isolation risks discovering, late, that a material choice complicates biocompatibility testing or that a design can't generate the evidence a UK Approved Body needs. Micrima and Medisyne show two versions of the same principle: one shaped around a specific standard from day one, the other keeping usability integrated throughout a compressed timeline, because there wasn't time to discover a problem afterwards.
EN 60601 is a family of standards for medical electrical equipment, and it remains a practical benchmark for compliance outside the EU. A manufacturer applies the standards relevant to the device’s intended use and configuration, including the base standard and any applicable collateral or particular standards, rather than every standard in the series.
The practical answer is running compliance work in parallel with design: testing early prototypes against key requirements, and building the risk management file (aligned to ISO 14971) as decisions are made rather than reconstructing it later. Our detailed EN 60601 guide covers this further.
A device that's technically compliant but hard to use creates real risk: misread displays, wrong controls pressed under pressure. Our guide to user experience and our piece on designing for clinical environments make the case that human-centric design needs to sit alongside engineering from the start, not get bolted on afterwards.
Medisyne's Influx device is a direct example: intuitive operation and easy cleaning were treated as core requirements from the brief, not secondary features, because busy hospital staff needed to use it safely and consistently under pressure.
Per our medical device planning guide, the same handful of mistakes recur:
We've worked with medical and scientific companies on device design and development for over two decades, including a breast-scanning diagnostic device for Micrima and a rapid-response device for Medisyne. We hold ISO 9001:2015 certification and typically work within a client's own ISO 13485 system rather than running a separate process alongside it, building ISO 13485, MDR, EN 60601, and UKCA considerations into design decisions from the start.
According to our own medical device design project data, this approach has contributed to production cost reductions of up to 30%, faster regional adaptation through modular design (up to 40% faster on one project), and reduced end-user training time by up to 50% through better usability.
If you're weighing up a regulatory consultancy against a design studio against a full-service partner, ask each one the same thing: can they point to a device where classification, standards, and design decisions were handled together, not passed down a chain? Micrima and Medisyne are our answers. It's worth putting the same question to anyone else on your shortlist.
Get in touch with our medical device design team to discuss your project.
Our expertise covers:
In addition to our medical device specialism, we also have extensive experience in industrial, sports and fitness, and consumer product design.
It varies by class and complexity. A self-declared Class I device reaches market far faster than a Class III device needing full UK Approved Body examination. Timelines can compress under pressure without skipping steps: Medisyne went from concept to hospital deployment in weeks, and Micrima had compliant prototypes ready in 12 weeks, both because classification and standards were built in from day one.
ISO 13485-aligned quality management is expected throughout the chain producing conformity evidence, not just at manufacturing. A design partner doesn't need its own certification, but its process needs to work inside the manufacturer's system.
UKCA applies to Great Britain. CE remains accepted there under transitional arrangements until 2028 or 2030 depending on device type, and is mandatory for Northern Ireland. As of July 2026, the MHRA is still deciding whether to extend or remove these deadlines.
Legal responsibility sits with the manufacturer placing the device on the market. A design partner contributes documentation, testing evidence, and design rationale, but the manufacturer carries the regulatory accountability.
Sometimes, but the starting point is establishing intended medical purpose and likely classification. A product not originally engineered for biocompatibility, sterilisation, or clinical durability often needs more redesign than it looks like it would.
Not necessarily, but a non-UK manufacturer must appoint a UK Responsible Person for MHRA registration and related obligations. UK-specific regulatory knowledge needs to sit somewhere in the team, regardless of where the design work happens.